Also trades as: 4527.T (JPX) · $vol 20M
RPHCF OTC
Rohto Pharmaceutical Co.,Ltd.
1W: +0.0%
1M: -1.1%
3M: -1.1%
YTD: -9.0%
1Y: +inf%
3Y: -29.3%
5Y: -74.5%
$15.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Balance Sheet Trends
Total Assets
$488.8B
+15.9% ▲
5Y CAGR: +199.0%
Total Liabilities
$166.6B
+10.8% ▲
5Y CAGR: +205.2%
Shareholders Equity
$303.7B
+16.8% ▲
5Y CAGR: +192.8%
Cash & Investments
$87.4B
+13.2% ▲
5Y CAGR: +10.5%
Total Debt
$60.6B
+20.7% ▲
5Y CAGR: +49.6%
Net Debt
-$26.7B
+0.7% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $582M | $585M | $89.2B | $77.2B | $87.4B |
| Short-Term Investments | $15M | $17M | $0 | $0 | $0 |
| Cash & ST Investments | $598M | $80.0B | $89.2B | $77.2B | $87.4B |
| Net Receivables | $33.3B | $39.7B | $44.7B | $47.1B | $77.3B |
| Inventory | $275M | $41.1B | $46.7B | $61.6B | $66.1B |
| Other Current Assets | -$32.8B | -$159.3B | $34.1B | $32.0B | $10.0B |
| Total Current Assets | $1.3B | $1.4B | $214.8B | $217.9B | $240.8B |
| Property, Plant & Equip. | $516M | $498M | $68.6B | $90.5B | $93.6B |
| Goodwill & Intangibles | $9.5B | $9.6B | $9.2B | $56.1B | $84.4B |
| Long-Term Investments | $231M | $253M | $0 | $0 | $56.3B |
| Other Non-Current Assets | -$9.4B | -$9.5B | $49.7B | $53.5B | $9.6B |
| Total Non-Current Assets | $906M | $899M | $131.4B | $204.0B | $248.0B |
| Total Assets | $2.3B | $2.3B | $346.2B | $421.9B | $488.8B |
| — Liabilities — | |||||
| Accounts Payable | $13.7B | $16.0B | $17.0B | $19.1B | $22.8B |
| Short-Term Debt | $8.0B | $4.2B | $5.3B | $7.0B | $24.9B |
| Deferred Revenue | $25M | $0 | $0 | $0 | $0 |
| Other Current Liabilities | -$24.3B | -$25.8B | $58.1B | $61.6B | $59.6B |
| Total Current Liabilities | $587M | $603M | $87.1B | $94.6B | $118.1B |
| Long-Term Debt | $13.3B | $7.5B | $5.2B | $43.2B | $28.4B |
| Other Non-Current Liab. | $4.5B | $5.8B | $2.7B | $10.6B | $2.0B |
| Total Non-Current Liabilities | $159M | $109M | $12.1B | $55.8B | $48.5B |
| Total Liabilities | $747M | $712M | $99.1B | $150.4B | $166.6B |
| — Equity — | |||||
| Common Stock | $53M | $6.5B | $6.5B | $6.5B | $6.5B |
| Retained Earnings | $1.3B | $184.0B | $209.4B | $228.4B | $258.2B |
| Accumulated OCI | $72M | $141M | $0 | $0 | $48.9B |
| Total Stockholders Equity | $1.5B | $1.6B | $246.3B | $260.1B | $303.7B |
| Total Liabilities & Equity | $2.3B | $2.3B | $346.2B | $421.9B | $488.8B |
| — Key Metrics — | |||||
| Total Debt | $21.4B | $102M | $10.5B | $50.2B | $60.6B |
| Net Debt | -$404M | -$482M | -$78.7B | -$26.9B | -$26.7B |
| Total Investments | $247M | $270M | $0 | $0 | $56.3B |